QUALIGEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.301 USD | +3.69% |
|
+3.61% | -45.27% |
Chart calendar Qualigen Therapeutics, Inc.
b.QDwpn9u7CKzNfqVZstx9qpKfrhgkSCZePyYSTKXY9oI.OUlG_vbsff6MD9QS87A0_sPWxSlHeEomelJgLfTqhegGZmPHvot44bwZwg~a9e260f5ac5cab191585992cc5edba44
Upcoming events on Qualigen Therapeutics, Inc.
Past events on Qualigen Therapeutics, Inc.
| 04/04/2024 | American Association for Cancer Research Meeting - Abstract #3320 |
| 04/04/2024 | American Association for Cancer Research Meeting - Abstract Number - #3350 |
| 04/04/2024 | American Association for Cancer Research Meeting - Abstract Number - #5928 |
| 04/04/2024 | American Association for Cancer Research Meeting - Abstract Number - #105 |
| 04/04/2024 | American Association for Cancer Research Meeting - Abstract Number - #576 |
| 21/10/2023 | American Association for Cancer Research in Breast Cancer Conference - Abstract :#B020 |
| 26/09/2023 | AACR Special Conference in Cancer Research: Pancreatic Cancer - Poster Number A080 |
| 26/09/2023 | AACR Special Conference in Cancer Research: Pancreatic Cancer - Poster Number A081 |
| 15/08/2023 13:30 | Q2 2023 Earnings Release |
| 12/07/2023 | Annual General Meeting |
| 01/06/2023 | American Society of Clinical Oncology Conference - A novel pan-RAS |
| 01/06/2023 | American Society of Clinical Oncology Conference - Impact of novel pan-RAS |
| 16/05/2023 13:00 | Q1 2023 Earnings Release |
| 02/05/2023 21:30 | Q4 2022 Earnings Release |
| 13/04/2023 | American Association for Cancer Research Meeting - Abstract No: 2708 |
| 04/03/2023 | American Association for Cancer Research Special Conference - A Novel RAS inhibitor for Pancreatic C |
| 04/03/2023 | American Association for Cancer Research Special Conference - A Novel RAS Inhibitor for Luminal B an |
| 15/11/2022 12:30 | Q3 2022 Earnings Release |
| 26/10/2022 20:30 | LD Micro Main Event Conference |
| 17/10/2022 | National Cancer Institute-sponsored Fourth RAS Initiative Symposium - Abstract #:40 |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 5,65 5,51 2.61% | 4,98 5,17 -3.64% | 3,66 3,20 14.41% | 0,00 |
|
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -22,7 -24,0 5.39% | -17,9 -18,5 3.23% | -11,3 -12,7 10.99% | -11,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -17,9 -18,8 4.83% | -21,3 -18,9 -12.7% | -12,5 -13,8 9.57% | -11,0 |
|
Net income Million USD | Released Forecast Spread | -17,9 -17,8 -0.52% | -18,6 -17,9 -4.38% | -13,4 -13,8 2.77% | -11,0 |
|
EPS USD | Released Forecast Spread | -6,10 -6,15 0.81% | -4,85 -4,76 -1.89% | -2,65 -2,70 1.85% | -1,00 |
| Announcement Date | 31/03/22 | 02/05/23 | 08/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,48 1,32 11.88% | 0,72 0,86 -16.09% | 1,43 1,20 19.21% | 1,44 1,62 -11.05% | 1,39 1,58 -11.75% | 1,61 1,40 14.8% | 1,63 1,60 1.69% | 0,43 0,50 -14.62% | 0,00 0,00 - |
|
EBIT Million USD | Released Forecast Spread | -4,65 -5,95 21.83% | -5,01 -5,86 14.56% | -4,14 -5,51 24.9% | -4,38 -5,43 19.21% | -4,41 -5,03 12.25% | -3,69 -4,55 18.84% | -3,55 -4,40 19.29% | -2,78 -4,90 43.3% | -2,27 -2,70 15.78% |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -6,06 -7,00 13.46% | -4,32 -6,80 36.48% | -4,12 -6,20 33.51% | -4,06 -6,10 33.51% | -8,80 -5,50 -60.05% | -4,27 -4,60 7.15% | -3,55 -4,40 19.41% | -3,24 -4,90 33.98% | -2,47 -2,70 8.43% |
|
Net income Million USD | Released Forecast Spread | -6,06 -7,00 13.42% | -4,32 -6,80 36.47% | -4,12 -6,20 33.49% | -3,83 -6,10 37.29% | -6,37 -5,03 -26.8% | -3,85 -4,60 16.39% | -3,46 -4,20 17.52% | -3,66 -4,70 22.2% | -2,45 -2,70 9.25% |
|
EPS USD | Released Forecast Spread | -2,00 -2,40 16.67% | -1,20 -1,90 36.84% | -1,10 -1,80 38.89% | -1,00 -1,60 37.5% | -1,55 -1,25 -24% | -0,78 -0,85 8.24% | -0,69 -0,52 -32.69% | -0,72 -0,92 21.74% | -0,47 -0,52 9.62% |
| Announcement Date | 31/03/22 | 13/05/22 | 15/08/22 | 14/11/22 | 02/05/23 | 15/05/23 | 14/08/23 | 14/11/23 | 08/04/24 |
More events
Past sector events for Qualigen Therapeutics, Inc.
| 02/05/2024 21:10 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:05 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:05 | RELAY THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:01 | GALAPAGOS NV: Q1 2024 Earnings Release |
| 02/05/2024 13:00 | ALNYLAM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 12:05 | SHATTUCK LABS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | BLUEPRINT MEDICINES CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | KYMERA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | IQVIA HOLDINGS INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:30 | MODERNA, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- QLGN Stock
- Calendar Qualigen Therapeutics, Inc.
